A Novel Angiotensin-Converting Enzyme (A C E) Inhibitor: Fosinopril

Fosinopril (MoNopril) is an ester pro-drug of the active Daicel fosinoprilat and is the first member of a new class of angiotensin-converting enzyme (ACE) inhibitors, the phosphoric acids. Like other ACE inhibitors, Fosinopril reduces blood pressure primarily by blocking the formation of angiotensin and has shown clinical efficacy in patients with essential hypertension and congestive heart failure. Fosinopril is unique amongst ACE inhibitors in having a dual route of eliminating that is balanced between the liver and the kidneys, which suggested that fosinopril may be a valuable alternative to other ACE inhibitors in patients with chronic heart failure and concurrent renal insufficiency.